The investigational compound, MIM-D3, is currently in Phase 2 development. It has been developed by Mimetogen Pharmaceuticals and could potentially be a new class of agents called TrkA agonists.
Dry eye therapies on the market increase tear production without addressing tear quality. MIM-D3 stimulates mucin production, which removes allergens, pathogens and debris in addition to lubricating the eye.
More Articles on Ophthalmology:
University of Oklahoma’s Dean McGee Eye Institute Receives $110k Grant from Research to Prevent Blindness
Florida Society of Ophthalmology Presents Dr. William Mallon With Leadership Award
Dr. J. Ryan McManus Joins Munson Medical Center Staff
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
